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MitochondriaParkinson's disease (PD) is a neurodegenerative disorder resulting frommitochondrial dysfunction indopaminergic
neurons. Mitochondria are believed to be responsible for cellular Mg2+ homeostasis. Mg2+ is indispensable for
maintaining ordinal cellular functions, hence perturbation of the cellular Mg2+ homeostasis may be responsible
for the disorders of physiological functions and diseases including PD. However, the changes in intracellular
Mg2+ concentration ([Mg2+]i) and the role of Mg2+ in PD have still been obscure. In this study, we investigated
[Mg2+]i and its effect on neurodegeneration in the 1-methyl-4-phenylpyridinium (MPP
+)model of PD in differen-
tiated PC12 cells. Application of MPP+ induced an increase in [Mg2+]i immediately via two different pathways:
Mg2+ release from mitochondria and Mg2+ inﬂux across cell membrane, and the increased [Mg2+]i sustained
for more than 16 h after MPP+ application. Suppression of Mg2+ inﬂux decreased the viability of the cells exposed
toMPP+. The cell viability correlated highly with [Mg2+]i. In the PC12 cells with suppressedMg
2+ inﬂux, ATP con-
centration decreased and the amount of reactive oxygen species (ROS) increased after an 8 h exposure to MPP+.
Our results indicate that the increase in [Mg2+]i inhibited cellular ROS generation andmaintained ATP production,
which resulted in the protection from MPP+ toxicity.
© 2015 Published by Elsevier B.V.1. Introduction
Parkinson's disease (PD) is a neurodegenerative disorder that is
caused by degradation of dopaminergic neurons in substantia nigra
[1]. Previous studies have demonstrated that the neuronal disorder is
accompanied by mitochondrial dysfunction [2,3]. In the dopaminergic
neurons in PD patients, mitochondrial morphological changes and
down-regulation of their function have been reported [4,5]. Moreover,
mutations in genes owing to mitochondrial quality control relate to fa-
milial PD [6,7], indicating that mitochondrial dysfunction was crucially
involved in PD. Inhibitors of complex I in the mitochondrial electron
transfer chain, such as 1-methyl-4-phenylpyridinium (MPP+) and rote-
none, induce PD-like degeneration in dopaminergic cells. Investigations
of cell death induced by these reagents are expected to clarify the un-
derlying mechanism of neurodegeneration in PD [1]. Down-regulation
of mitochondrial functions results in the depletion of cellular ATP, gen-
eration of reactive oxygen species (ROS) [8] andﬁnally the release of ap-
optosis inducers to the cytoplasm [9,10]. Therefore, it can be concluded
that mitochondria play a pivotal role in PD.
In previous studies conducted by our group, itwas demonstrated that
mitochondria play an important role in cellular Mg2+ homeostasis[11–14]. Mg2+ is an essential cation for a number of physiological pro-
cesses including mitochondrial functions [15,16]. The Mg2+ concentra-
tion in mitochondria modulates mitochondrial ATP synthesis [17,18].
Mg2+ around mitochondria suppresses Ca2+-induced ROS generation
and the formation of mitochondrial permeability transition pore [19].
These reports indicate that Mg2+ transport across the cellular and mito-
chondrial membrane is involved in the regulation of cellular energy me-
tabolism and apoptosis. Recent studies have demonstrated the
importance of Mg2+ in cellular functions further: second messenger
role in T-cells [20], regulation of neuronal development [21], and modu-
lation of electric synapses [22]. Due to the importance of this ion, deﬁ-
ciency of Mg2+ has been linked to the disorder of physiological
functions anddiseases including PD [23,24]. However,whether the intra-
cellular Mg2+ concentration ([Mg2+]i) changes in neuronal disorders
and whether it plays pivotal roles in the process of disease have still
been obscure.
Low Mg2+ concentrations in the brain tissues of PD patients have
previously been reported [23]. We also demonstrated that MPP+,
which induces PD-like dopaminergic cell death, induced acuteMg2+ re-
lease from mitochondria in PC12 cells [25]. These studies suggest that
the perturbation of Mg2+ in the cells and in the mitochondria would
be involved in the process of neurodegeneration in PD. Moreover, it
has been reported that Mg2+ supplementation in a culture medium
protects cells from neurodegeneration in cellular model of PD [26], sug-
gesting that Mg2+ may have important role in neuroprotection. In this
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and its mechanisms. We also estimated the contribution of intracellular
Mg2+ to cell viability in the MPP+ model of PD in PC12 cells.
2. Materials and methods
2.1. Cell culture
PC12 cells were obtained from the Riken Tsukuba Institute, and cul-
tured in a Dulbecco's modiﬁed Eagle'smedium (DMEM) containing 10%
horse serum, 5% fetal bovine serum (FBS), 50 U/mL penicillin and
50 μg/mL streptomycin at 37 °C in the CO2 incubator. For ﬂuorescence
measurements, the cells were cultured on poly-D-lysine (PDL)-coated
glass bottom dishes. For experimental use, cells were differentiated by
culturing in a serum-free medium with 50 ng/mL nerve growth factor
(NGF) for 5 days.
2.2. Fluorescence imaging
To measure the changes in [Mg2+]i and intracellular Ca2+ concen-
tration ([Ca2+]i), mag-fura-2-AM and fura-2-AM (Invitrogen, Carlsbad,
CA, USA)were used, respectively.Mag-fura-2-AMor fura-2-AMwas ap-
plied to the culture medium at 2 μM, and the cells were incubated at
37 °C for 30min. The cells were then washed twice with an experimen-
tal medium containing (in mM): NaCl, 125; KCl, 5; CaCl2, 2; MgSO4, 1.2;
KH2PO4, 1.2; D-glucose, 6; HEPES, 25 (pH adjusted to 7.4 with NaOH)
and further incubated in the experimental medium at 37 °C for 15 min
to allow for complete hydrolysis of the acetoxymethyl (AM) ester
form. For the experiments performed in Mg2+-free or Ca2+-free condi-
tion, the experimental medium was replaced to the medium without
MgSO4 (nominally Mg2+-free experimental medium) or that without
CaCl2 (nominally Ca2+-free experimental medium) at the washing pro-
cedure, and cells were incubated at 37 °C for 15 min to allow complete
hydrolysis of the AMester form of ﬂuorescent dyes in eachmedium. Os-
molarity of normal, nominally Mg2+-free and nominally Ca2+-free ex-
perimental medium were 296, 294 and 291 mOsmol/kg, respectively.
The osmolarity was measured with a freezing point osmometer,
OSMOMAT 3000D (Gonotec, Berlin, Germany). In some experiments,
mag-fura-2-AM was used at 10 μM to chelate intracellular Mg2+.
Fluorescence of mag-fura-2 and fura-2 were measured on a ﬂuores-
cencemicroscope ECLIPSE TE300 (Nikon, Tokyo, Japan) equippedwith a
20× objective lens (S Fluor, Nikon). A 150 W Xe lamp was used as the
source of excitation, and a light of a suitable wavelength was selected
with the monochrometer unit. Mag-fura-2 and fura-2 were excited at
340 nm (Mg2+ or Ca2+ bound) and 380 nm (Mg2+ or Ca2+ unbound),
alternatively. The ﬂuorescencewas detectedwith a CCD camera (HiSCA,
Hamamatsu photonics, Shizuoka, Japan) through a 400 nm dichroic
mirror and a 535/55 nm emission ﬁlter. Analysis was conducted with
Aquacosmos software (Hamamatsu photonics). Fluorescence intensi-
ties were calculated as mean intensities in the region of interest (ROI)
containing the entire cell body.
2.3. Calibration of [Mg2+]i and [Ca
2+]i
[Mg2+]i and [Ca2+]i were estimated from the ﬂuorescence ratio of
mag-fura-2 and fura-2 respectively, following a previous study [27].
To estimate Rmax and Rmin for mag-fura-2, PC12 cells were incubated
in a high-Mg2+ medium containing (in mM): NaCl, 125; KCl, 5;
MgSO4, 100; KH2PO4, 1.2; D-glucose, 6; HEPES, 25 (pH adjusted to 7.4
with NaOH) or in Mg2+-chelated medium added 50 mM EDTA to the
experimental medium for 10 min with 0.00125% digitonin. Digitonin
waswashed out and cells were further incubated in the high-Mg2+me-
dium or Mg2+-chelated medium for 30 min. Then, the cells were
stained with mag-fura-2, and ﬂuorescence was measured in these
media, respectively. To estimate Rmax and Rmin for fura-2, fura-2 loaded
PC12 cells were incubated in the experimental medium or absolutelyCa2+-free medium containing (in mM): NaCl, 125; KCl, 5; MgSO4, 1.2;
KH2PO4, 1.2; EGTA, 1; D-glucose, 6; HEPES, 25 (pH adjusted to 7.4 with
NaOH) for 15 min with 5 μM ionocycin. Then, the ﬂuorescence was
measured.
2.4. Measurement of intracellular total divalent cation concentration
Total amounts of intracellular Ca2+ and Mg2+ were measured with
inductively coupled plasma atomic emission spectroscopy (ICP-AES).
Control andMPP+ treated cellswerewashed twice using PBS, harvested
in ice-cold PBS and centrifuged at 4 °C, 800 ×g for 3 min. The superna-
tant was discarded, the cells were resuspended in 1 mL ice-cold PBS
and sonicated. 200 μL of cell lysatewas used tomeasure protein concen-
tration in the sample. Mg2+ and Ca2+ concentrations in the remaining
800 μL were measured with ICP-AES at Shimadzu Techno-Research
(Kyoto, Japan). Protein concentration in each sample was measured
using a protein assaywith coomassie brilliant blue (CBB) (Nakaraitesqu,
Osaka, Japan). Absorbance at 570 nm was measured with a microplate
reader (Fluoroskan Ascent FL, Thermo Fisher Scientiﬁc, Waltham, MA,
USA).Mg2+ andCa2+ concentrationsmeasuredwith ICP-AESwere nor-
malized to the protein concentration in each sample.
2.5. Measurement of cell viability
Cell viability was measured using the MTT assay. After exposure to
MPP+, the culture medium was replaced with the medium containing
0.5mg/mL of MTT, and cells were incubated for 2 h at 37 °C. The culture
medium was removed and 100 μL of dimethyl sulfoxide was added in
each well to dissolve the precipitation, and the absorbance at 570 nm
was measured using a microplate reader. Cell viability was calculated
as a ratio of the control culture value.
2.6. Stable expression of SLC41A2 in PC12 cells
Total RNA was isolated from PC12 cells and puriﬁed using the
RNeasy mini kit (QIAGEN, Tokyo, Japan). The total RNA was treated
with TURBO DNase (Ambion, CA, USA), and single-stranded cDNA was
generated by reverse transcription using SuperScript VILO (Invitrogen).
DNA coding SLC41A2 was ampliﬁed with PCR and inserted in the
pEGFP-C1 vector (Takara, Siga, Japan) at the BglII and the ApaI restric-
tion enzyme sites. The vectorwas transfected to PC12 cells with Lipofec-
tamine LTX. Two days after transfection, the cells were cultured and
screened in the culture medium containing 500 ng/mL of genetisin
(Invitrogen) for 2 weeks. The remaining cells, most of which likely pos-
sess the transfected gene, were suspended, diluted to 2.5 cells/mL in the
culture medium containing genetisin and plated in a 96 well plate
(200 μL for each well). The wells containing only one cell were selected,
and the expression of EGFP was conﬁrmed. The cells that emit EGFP
ﬂuorescence and can proliferate in genetisin containing the medium
were the ones stably expressing the transfected gene.
2.7. Real-time PCR
Total RNA from PC12 cells were isolated and puriﬁed by using the
RNeasy mini kit. The total RNA was treated with Terbo DNase, and
single-stranded cDNA was generated by reverse transcription by using
SuperScript VILO. Real-time PCR was carried out with SYBR GreenER™
(Invitrogen). Primers usedwere as follows: for SLC41A2 (forward primer,
5′- ATTACCTCAGCCATTCCATACTCC; reverse primer, 5′- AGCCAACGATAA
CTCCAACCA) and for hydroxymethiylbilane synthase (Hmbs), (forward
primer, 5′- TCTAGATGGCTCAGATAGCATGCA; reverse primer, 5′- TGGA
CCATCTTCTTGCTGAACA). Hmbs was used as a housekeeping gene.
Real-time PCR was performed by using Rotor-Gene (QIAGEN) for 40 cy-
cles. Data was quantiﬁed with the comparative Ct quantiﬁcation method
by plotting cycle number at threshold. Expression levels of SLC41A2were
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trol PC12 cells were compared.
2.8. Measurement of intracellular ATP concentration
To measure intracellular ATP concentration, a genetically encoded
ATP sensor, ATeam, was expressed in PC12 cells [28]. Four days after
NGF supplementation, the plasmid coding ATeam was transfected to
the PC12 cells by using Lipofectamine LTX (Invitrogen). The next day,
cells were exposed to MPP+ and the ﬂuorescence signals of ATeam
were observed.
The ﬂuorescence of ATeam was measured using a confocal laser
scanning microscope system (FluoView FV1000, Olympus, Tokyo,
Japan) mounted on an inverted microscope (IX81, Olympus) with a
40× oil-immersion objective lens. ATeam was excited at 440 nm from
the laser diode, and the ﬂuorescence signals were separated using a
510 nm dichroic mirror and observed at 460–500 nm for cyan ﬂuores-
cent protein (CFP) and 515–615 nm for yellow ﬂuorescent protein
(YFP). Fluorescence images were acquired with photomultipliers and
analyzed with the FluoView software package (Olympus). Fluorescence
intensities were calculated as the mean intensity over a deﬁned ROI
containing the entire cell body of each cell. The intracellular ATP con-
centration corresponds to the ﬂuorescence ratio (YFP/CFP).
2.9. Measurement of intracellular ROS
Intracellular ROSwasmeasured using a total ROS detection kit (Enzo
Life Sciences, NewYork, USA). Differentiated PC12 cellswere exposed to
0 or 3 mMMPP+ for 8 h. The MPP+ containing a culture medium was
replaced with a culture medium containing 500 nM of an oxidative
stress detection reagent. The cells were incubated at 37 °C for 30 min
and washed twice with a wash buffer. The dish was then ﬁlled with a
fresh experimental medium. Fluorescence was measured with a ﬂuo-
rescence microscope, ECLIPSE TE300 as described above. The probe
was excited at 488 nm and the ﬂuorescence was detected with a CCD
camera through a 505 nm dichroic mirror and a 535/55 nm emission
ﬁlter.
2.10. Statistical analysis
Signiﬁcant differences were determined using the Student's t-test
for the comparison of two sets of data and using Dunnett's test for mul-
tiple comparisons. The P values of less than 0.05 were considered to be
signiﬁcantly different.
3. Results
3.1. MPP+ induces dosage- and time-dependent cell death in differentiated
PC12 cells
The dosage- and time-dependent change in viability of PC12 cells to
MPP+ toxicity were estimated. We found that exposure to 3 mM of
MPP+ for 24 h induced about 50% cell death (Fig. S1A). Relationship be-
tween the concentration of MPP+ and the cell viability was in agree-
ment with the previously reported study on MPP+ toxicity using
differentiated PC12 cells [9]. In the medium containing 3 mM of
MPP+, the cell viability did not change for 6 h, and it decreased to 90%
in 8 h and to 70% in 16 h (Fig. S1B). Based on these results, MPP+ at a
concentration of 3 mMwas used, and the effects of MPP+ at the onset
of the cell death (8 h) and/or at the further progressed stage (16 h)
were estimated.
3.2. MPP+ immediately alters intracellular divalent cation concentration
To estimate the effects of MPP+ on intracellular divalent cation con-
centration, changes in [Mg2+]i and [Ca2+]i were measured using mag-fura-2 and fura-2, respectively. These probes are useful tools to compare
the [Mg2+]i and [Ca2+]i quantitatively in the cells under various condi-
tions, because they are ratiometric probes. Although mag-fura-2 has
been used as a ﬂuorescent Mg2+ probe, it is sometimes used as a low
afﬁnity Ca2+ indicator [29] because it has a low Kd value for Ca2+
[30]. Therefore, we must conﬁrm that the ﬂuorescent signal from
mag-fura-2 results not from Ca2+ but fromMg2+.
At ﬁrst, changes in [Mg2+]i and [Ca2+]i immediately after MPP+ ap-
plication were observed. [Mg2+]i in differentiated PC12 cells was cali-
brated using mag-fura-2 ratio. It was about 0.5 mM in the steady state.
MPP+ induced an increase in [Mg2+]i to about 0.65 mM immediately
after its application, and [Mg2+]i maintained the increased level for
more than 10 min (Fig. 1A and B). [Ca2+]i in the steady state was esti-
mated to be about 80 nM. [Ca2+]i also increased to about 130 nM in
2 min in response to MPP+ application, and then decreased to basal
concentration gradually (Fig. 1C). In a nominally Ca2+-free experimen-
tal medium, [Ca2+]i in steady state was low (about 20 nM), and an in-
crease in [Ca2+]i in response to MPP+ was abolished (Fig. 1C and D).
The increase in the mag-fura-2 signal in response to MPP+ was not
changed in a nominally Ca2+-free experimental medium (Fig. 1B).
Therefore, we concluded that the change in the mag-fura-2 signal indi-
cated the change in [Mg2+]i without interference from the Ca2+ signal.
Our previous study demonstrated that MPP+ elicits a decrease in
Mg2+ concentration in mitochondria in PC12 cells by monitoring the
change in theMg2+ concentration inside themitochondria [25]. It is like-
ly that the Mg2+ was released from the mitochondria to the cytoplasm.
To further study the Mg2+ release, MPP+ was applied to the cells pre-
treated with carbonyl cyanide p-(triﬂuoromethoxy) phenylhydrazone
(FCCP). FCCP is an uncoupler for the mitochondrial inner membrane,
and the collapse of their membrane potential induces Mg2+ release
frommitochondria [14]. Therefore, pre-treatmentwith FCCPwould abol-
ish MPP+-induced Mg2+ release from mitochondria. FCCP was added to
an experimental medium 10 min prior to MPP+ application. FCCP in-
duced about 0.4 mM increase in [Mg2+]i (from 0.5 to 0.9 mM, Fig. S2).
Whereas [Mg2+]i also increased in response to following MPP+ applica-
tion, the increased concentration (about 0.1 mM) was a signiﬁcantly
smaller value than control (Fig. 1B). It indicates that mitochondria partly
contribute to the increase in [Mg2+]i, and there might be other mecha-
nisms to induce the increase in [Mg2+]i in response toMPP+ application.
To evaluate the contribution ofMg2+ inﬂux, [Mg2+]iwasmeasured in
a nominally Mg2+-free experimental medium. Whereas [Mg2+]i in
steady statewas not affected in a nominallyMg2+-free experimentalme-
dium, the increase in [Mg2+]i was signiﬁcantly attenuated. Moreover, it
was completely suppressed in the cells pre-treatedwith FCCP in the nom-
inally Mg2+-free experimental medium (Fig. 1C and D). These results in-
dicate that anMPP+-induced increase in [Mg2+]iwas composed ofMg2+
mobilization via two different pathways: Mg2+ inﬂux and Mg2+ release
frommitochondria. On the other hand, the increase in [Ca2+]i wasmostly
abolished in a nominally Ca2+-free experimental medium, and pre-
treatmentwith FCCPhadnoeffect on it in the nominally Ca2+-free exper-
imental medium (Fig. 1C and D). These results indicate that the increase
in [Ca2+]i mainly results from Ca2+ inﬂux.
TRPM7, which is a cation channel expressing on cell membrane,
plays an important role in cellular Mg2+ homeostasis [31]. We exam-
ined the contribution of these channels to the [Mg2+]i increase. The in-
creases in [Mg2+]i and [Ca2+]i in response to MPP+ were signiﬁcantly
attenuated in the presence of 50 μM of 2-aminoethoxydiphenyl borate
(2-APB) (Fig. 1B and D), which is an inhibitor of Ca2+ permeable chan-
nels including TRPM7 [32,33]. It suggests that MPP+ or a downstream
intracellular signal activated Mg2+ inﬂux and Ca2+ inﬂux via TRPM7.
Moreover, the Mg2+ inﬂux was partly suppressed by 40 μM of imipra-
mine (Fig. 1B). Imipramine was used at the concentration that has no
toxicity to differentiated PC12 cells for 16 h. Although imipramine is
known as an inhibitor of Na+/Mg2+ exchanger working asMg2+ extru-
sionmechanism, it also inhibits Mg2+ inﬂux via TRPM-like channel [34]
and via reversible type Na+/Mg2+ exchanger [35] across a cell
Fig. 1. Changes in [Mg2+]i immediately after MPP+ application. (A) Averaged time-courses of [Mg2+]i in response toMPP+ (3mM) in normal experimental medium (control; black line,
n= 207 cells from 16 experiments) and nominallyMg2+-free experimental medium (gray line, n= 105 cells from 8 experiments). (B) Comparison of the changes in [Mg2+]i in response
to MPP+ under various conditions (Control (normal experimental medium), n = 207 cells from 16 experiments; Ca2+-free (nominally Ca2+-free experimental medium), n = 77 cells
from 7 experiments; Mg2+-free (nominally Mg2+-free medium), n = 105 cells from 8 experiments; FCCP (5 μM) pre-treatment, n = 110 cells from 8 experiments; Mg2+-free FCCP
pre-treatment, n = 60 cells from 5 experiments; Imipramine (40 μM), n= 108 cells from 8 experiments; 2-APB (50 μM), n= 156 from 11 experiments). The change in [Mg2+]i was cal-
culated as the difference between averaged concentration from−1 to 0min and that from4 to 5min in time-course of each cell. (C) Averaged time-courses of [Ca2+]i in response toMPP+
in normal experimental medium (control; black line, n = 186 cells from 9 experiments) and nominally Ca2+-free experimental medium (gray line, n = 169 cells from 9 experiments).
(D) Comparison of the changes in [Ca2+]i in response toMPP+under various conditions (Control (normal experimentalmedium), n=186 cells from9 experiments; Ca2+-free (nominally
Ca2+-free experimental medium), n = 169 cells from 9 experiments; Ca2+-free FCCP Pre-treatment, n = 50 cells from 3 experiments; 2-APB, n = 60 cells from 4 experiments). Time-
courses and bar graphs are represented as mean ± SEM. * indicates P b 0.05 in Dunnett's test.
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ﬂux across the cell membrane.3.3. Mg2+ inﬂux causes a sustained increase in intracellular Mg2+
MPP+ induced an increase in [Mg2+]i and [Ca2+]i immediately after
its application, and [Mg2+]i remained at the increased concentration for
at least 10 min while [Ca2+]i gradually decreased in 10 min. To deter-
mine the changes in divalent cation concentrations depending on the
progress of the cell death induced by MPP+, [Mg2+]i and [Ca2+]i in
the cells exposed toMPP+ for 8 and 16 hweremeasured and compared
with those in the cells not exposed to MPP+ (control). The [Mg2+]i in
the cells exposed to MPP+ for 8 and 16 h remained higher (about
0.7 mM) than that in non-exposed cells (Fig. 2A). On the other hand,
[Ca2+]i in the cells exposed to MPP+ for 8 h showed almost the same
levels to non-exposed cells (8 h and control in Fig. 2B). It indicates
that MPP+ induced a transient increase in [Ca2+]i immediately after
its application, and then [Ca2+]i returned to the basal level and
remained in it for at least 8 h. [Ca2+]i increased again after a 16 h expo-
sure to MPP+; it probably resulted from the increase in [Ca2+]i as a cell
death signal [36]. These results indicate that MPP+ induced-[Ca2+]i in-
crease has two phases. The time-course in [Ca2+]i was different fromthat in [Mg2+]i. It also makes sure that the changes in mag-fura-2
ratio were the result of changes in [Mg2+]i not the changes in [Ca2+]i.
Cellular total Mg2+ and Ca2+ contents weremeasured to determine
that the increase in [Mg2+]i results fromMg2+ inﬂux. More than 90% of
cellular Mg2+ is not free and is bound to intracellular biological mole-
cules, hence [Mg2+]i might be altered without ion transport across the
cell membrane. If the increase in [Mg2+]i originated from the extracel-
lular medium, total cellular Mg2+ content would increase. Therefore,
the total cellular Mg2+ and Ca2+ contents were measured with ICP-
AES. Total cellular Mg2+ content signiﬁcantly increased at 16 h
(Fig. 2C), whereas total Ca2+ content did not alter in 16 h (Fig. 2D).
These results indicate that MPP+ induced a continuous Mg2+ inﬂux.
This caused a sustained increase in [Mg2+]i and an increase in cellular
total Mg2+ content after 16 h.
3.4. Intracellular Mg2+ level determines cell viability
The Mg2+ inﬂux contributed to the increase in [Mg2+]i, hence its in-
hibitionwould alter the [Mg2+]i after 16 h. As shown in Fig. 1B, theMg2+
inﬂux induced by MPP+ was suppressed in nominally Mg2+-free medi-
um and also in an imipramine containing medium. 16 h after exposure
to MPP+, MPP+-induced increase in [Mg2+]i was also suppressed
under those conditions, whereas it was potentiated under high Mg2+
Fig. 2. Comparison of intracellular Mg2+ and Ca2+ concentrations. (A) [Mg2+]i in the cells not exposed to MPP+ (Control, n = 341 cells from 7 experiments) and in the cells exposed to
3 mM ofMPP+ for 8 h (n= 198 cells from 4 experiments) and 16 h (n= 392 cells from 5 experiments) were compared. [Mg2+]i was calculated frommag-fura-2 ratio. (B) [Ca2+]i in the
cells not exposed toMPP+ (control, n=1077 cells from10experiments) and in the cells exposed to 3mMofMPP+ for 8 h (n=687 cells from7 experiments) and 16h (n=649 cells from
7 experiments)were compared. [Ca2+]i was calculated from fura-2 ratio. (C) Cellular totalMg2+ concentration in the cells not exposed toMPP+ (control) and in the cells exposed to 3mM
ofMPP+ for 8 and 16 hwere compared (n=3 samples for each condition). (D) Intracellular total Ca2+ concentration in the cells not exposed toMPP+ (control) and in the cells exposed to
3 mM of MPP+ for 8 and 16 h were compared (n = 3 samples for each condition). Data are represented as mean ± SEM. * indicates P b 0.05 in Dunnett's test.
Fig. 3. IntracellularMg2+ level determines cell viability. (A) Comparison of [Mg2+]i after 16 h exposure toMPP+ innormal culturemedium (containing 0.8mMMg2+, n=563 cells from7
experiments), in nominallyMg2+-free culturemedium (n=175 cells from 4 experiments), in imipramine (40 μM) containing culturemedium (n=339 cells from8 experiments) and in
high-Mg2+ (4mM) culture medium (n= 345 cells from 3 experiments). (B) Comparison of cell viability after 16 h exposure to MPP+ in normal culture medium (n= 38), in nominally
Mg2+-free culturemedium(n=16), in imipramine containing culturemedium (n=16) and inhigh-Mg2+ culturemedium (n=18). (C) The cell viabilities shown in panel Bwerehighly
correlated with the [Mg2+]i shown in panel A (black line, R2 = 0.94). [Mg2+]i in non-exposed cells (data from Fig. 2A control) was indicated as mean (gray line at 0.286 in mag-fura-2
ratio) ± SEM (light gray region). Data are represented as mean ± SEM. * indicates P b 0.05 in Dunnett's test.
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16 h in each conditionwas correlatedwith the [Mg2+]i concentration im-
mediately after MPP+ application shown in Fig. 1B. Moreover, [Mg2+]i in
the nominally Mg2+-free medium shown in Fig. 3A was almost at the
same concentration (about 0.5 mM) with that in non-treated cells (con-
trol in Fig. 2A), suggesting that the Mg2+ release frommitochondria had
no effect on the [Mg2+]i after 16 h, and the Mg2+ inﬂux mainly contrib-
uted to it. Therefore, we concluded that modulation ofMg2+ inﬂux alters
[Mg2+]i during neurodegeneration.
We examined the effect of the [Mg2+]i onMPP+-induced cell death.
In a normal culture medium (DMEM containing NGF), 70% of the cells
were viable after 16 h exposure toMPP+ (Fig. 3B). InMg2+-free culture
medium, the toxicity of MPP+ accelerated, and the cell viability reduced
to 25%. It also decreased to 40% in an imipramine containing cultureme-
dium. An increase in Mg2+ concentration in the culture medium to
4 mM partly but not signiﬁcantly attenuated the toxicity. Incubation in
these conditions without MPP+ had no effect on the cell viability in
16 h (Fig. S3A). The cell viability correlated with [Mg2+]i measured in
the same condition (R2 = 0.98, Fig. 3C). These results suggest that
[Mg2+]i is a crucial factor that determines cell viability inMPP+ toxicity.
To ascertain the contribution of [Mg2+]i to cell viability, [Mg2+]i was
altered and the effect on cell viability was estimated. When mag-fura-2-
AM was used at 10 μM, MPP+-induced increase in [Mg2+]i was not ob-
served (Fig. 4A). Since the ﬂuorescent ion probes bind to the targeted
ion, they also act as chelators of targeted ions and an excessive load of
probe to cells affects cellular ion dynamics.MPP+-inducedMg2+ increase
was not observed by using mag-fura-2-AM at higher concentration than
5 μM (Figure S4). The cell viability after 16 h exposure to MPP+ was sig-
niﬁcantly decreased in the Mg2+-chelated cells (Fig. 4B). This concentra-
tion of mag-fura-2 had no effect on cell viability in the culture medium
without MPP+ in 16 h (Fig. S3B). Next, we tried to increase [Mg2+]i and
estimate the effect of high [Mg2+]i on MPP+ toxicity. To achieve it, PC12
cells stably overexpressing one of the Mg2+ transporters, SLC41A2,
which has been reported to increase Mg2+ inﬂux across the cell mem-
brane [37], was prepared. Expression level of SLC41A2 in constitutively
overexpressed cells was 1.8-fold higher than that in control cells
(Fig. S5). Although it has been reported that SLC41A2 is localized to
organelle'smembrane [38], constitutively overexpressed SLC41A2 tagged
by EGFP was localized not only to intracellular compartments but also to
plasma membrane (Fig. S6). The authors pointed out the possibility that
theplasmamembrane localization of SLC41A2 reﬂect aberrant cell surface
transport due to overexpression [38]; it successfully achieved to increase
[Mg2+]i under steady state compared with that in normal cells (control).
Cell viability after a 16 h exposure to MPP+ was also higher in
overexpressed cells (Fig. 5B). These results indicate that [Mg2+]i is anFig. 4. Chelation of intracellular Mg2+ accelerated the toxicity of MPP+. (A) Averaged time-cou
fura-2-AM at 10 μM (black line, n = 67 cells from 4 experiments) and at 2 μM (gray line, n =
viabilities after 16 h exposure to MPP+ in normal culture medium (Control, n = 12) and in cu
sented as mean ± SEM. * indicates P b 0.05 in t-test.important factor that determines the cell viability in MPP+ toxicity, and
overexpression of SLC41A2 attenuates the toxicity by increasing
[Mg2+]i. The next question is whether this Mg2+ transport protein alters
the expression level in the progress of PD. We estimated the relative ex-
pression level of mRNA encoding SLC41A2 using real-time PCR at 8 and
16 h after MPP+ treatment and compared with that of non-treated cells.
It increased to 1.8 fold compared to non-treated cells after 16 h exposure
to MPP+ (Fig. 5C).
3.5. Mg2+ works as an inhibitor of ROS generation and maintains cellular
ATP concentration
Previous studies indicate that mitochondrial dysfunction and accel-
eration of ROS production are typical features observed in the neurode-
generation in PD [8]. Mitochondrial activities link to cellular ATP
synthesis, and ROS is one of the key regulators of MPP+ induced cell
death. [Mg2+]i would attribute to these regulators of neurodegenera-
tion before the onset of cell death. Therefore, the effect of the altered
[Mg2+]i was investigated to determine any effect on cellular ATP con-
centration and ROS generation at 8 h afterMPP+ exposure, when the vi-
ability started to decrease (Fig. S1). ATP concentration, which was
measured with an ATP sensor, ATeam [28], decreased signiﬁcantly in
the cells exposed toMPP+ for 8 h in a nominallyMg2+-free cultureme-
dium(Fig. 6). This result indicates thatMg2+ is required formaintaining
cellular ATP concentration. ROS generation after an 8 h exposure to
MPP+ accelerated in the cells exposed to MPP+ in a nominally Mg2+-
free culturemedium, and itwas inhibited in the cells in a highMg2+ cul-
ture medium (Fig. 7). These data indicate that effects of the increase in
[Mg2+]i are maintaining cellular ATP production and inhibition of ROS
generation. As a consequence, the increase in [Mg2+]i protects dopami-
nergic cells from neurodegeneration in PD.
4. Discussion
4.1. Summary of this work
Recent studies have demonstrated that Mg2+ is an indispensable
ion for ordinal cellular functions [20,21]. Therefore, a disturbed Mg2+
homeostasis has been implicated in a number of diseases [39–41]. In
the case of PD, it has been shown that Mg2+ has protective effects
in vivo and in vitro experiments [26,42]. However, the underlying
mechanisms remain obscure. In this study, we investigated intracellular
Mg2+ concentration and its effect on neurodegeneration in the MPP+
model of PD in neuronally differentiated PC12 cells. The results of our
experiments showed that: 1) MPP+ induced an increase in [Mg2+]irses of the changes in mag-fura-2 ratio in response to MPP+ in the cells loadedwith mag-
207 cells from 16 experiments, the same data as Fig. 1A control). (B) Comparison of cell
lture medium containing 10 μM of mag-fura-2-AM (mag-fura-2, n = 12). Data are repre-
Fig. 5. Increase in [Mg2+]i attenuated the toxicity of MPP+. (A) Comparison of [Mg2+]i in
control cells (n = 444 cells from 9 experiments) and in SLC41A2 overexpressed cells
(n = 232 cells from 9 experiments) in steady state. (B) Comparison of cell viability after
16 h exposure to MPP+ in control cells (n = 36) and in SLC41A2 overexpressed cells
(n=36). (C) Comparison ofmRNA expression levels of SLC41A2 in non-exposed cells (con-
trol) and in the cells exposed to 3 mM of MPP+ for 8 and 16 h (n = 10 samples for each).
Data are represented as mean ± SEM. * indicates P b 0.05 in t-test (A and B) and Dunnett's
test (C).
Fig. 7. Effects of [Mg2+]i on cellular ROS amount. Comparison of intracellular ROS in non-
exposed cells (Control, n=540 cells from4 experiments), in the cells after 8 h exposure to
MPP+ in nominally Mg2+-free culture medium (n = 549 cells from 5 experiments), nor-
mal culture medium (n = 652 cells from 5 experiments) Mg2+ 4 mM culture medium
(n= 740 cells from 5 experiments) and imipramine (40 μM) containing culture medium
(n = 670 cells from 5 experiments). Fluorescent intensity of ROS detection probe corre-
sponds to intracellular ROS. Data are represented as mean ± SEM. * indicates P b 0.05 in
Dunnett's test.
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zation from the mitochondria and an inﬂux across the cell membrane
(Fig. 1), 2) the Mg2+ inﬂux sustained and resulted in the chronic in-
crease in [Mg2+]i and cellular total Mg2+ concentration (Fig. 2),Fig. 6. Effects of [Mg2+]i on cellular ATP concentration. Comparison of ATeam ratio, which
corresponds to cellular ATP concentration, in non-exposed cells (Control, n = 80 cells
from 4 experiments), the cells after 8 h exposure toMPP+ in nominallyMg2+-free culture
medium (n= 75 cells from 4 experiments), in normal culturemedium (n= 79 cells from
4 experiments), in Mg2+ 4 mM culture medium (n = 76 cells from 4 experiments) and
Imipramine (40 μM) containing culture medium (n = 54 cells from 3 experiments).
Data are represented as mean ± SEM. * indicates P b 0.05 in Dunnett's test.3) modulation of Mg2+ inﬂux altered [Mg2+]i during MPP+-induced
neurodegeneration (Fig. 3), 4) the viability of the cells exposed to
MPP+ was altered depending on intracellular Mg2+ level (Figs. 3–5),
and 5) the cellular ATP concentration was maintained and ROS genera-
tion was suppressed by the increased [Mg2+]i (Fig. 6, 7). We demon-
strated that MPP+ induced an increase in [Mg2+]i in neuronally
differentiated PC12 cells. Whereas MPP+ is a neurotoxic reagent,
MPP+-induced increase in [Mg2+]i attenuated the toxicity. MPP+ elicit-
ed these two effects concomitantly. It caused to elucidate a crucial role
for Mg2+ in the neuroprotection in MPP+model of PD. Although a pre-
vious study revealed that supplementation of Mg2+ in a culture medi-
um has a protective effect on neurodegeneration in MPP+ model of
PD [26], the underlying mechanisms have still been obscure. Our data
obtained in this study clearly showed that intracellular Mg2+ prevents
the generation of ROS, which is a main mediator of neurodegeneration
in PD, and maintains cellular ATP concentration, resulting in neuropro-
tection. To the best of our knowledge, this is the ﬁrst study that clariﬁes
the underlying mechanisms in the protective effect of Mg2+ in the cel-
lular model of PD.4.2. Cellular Mg2+ transport induced by MPP+
In this study, we demonstrated that MPP+, which is an inducer of
PD-like neurodegeneration in dopaminergic cells, elicits an increase in
[Mg2+]i via two different pathways (Fig. 1). The primary pathway is
Mg2+ inﬂux from an extracellularmedium. Althoughwhat protein per-
meatedMg2+ in response toMPP+ is still obscure, our data suggest that
one possible channel is TRPM7 because 2-APB, which is an inhibitor of
Mg2+ transport via this channel, partly attenuated an MPP+-induced
increase in [Mg2+]i and mostly suppressed the [Ca2+]i response
(Fig. 1B and D). Moreover, imipramine, which is known as an inhibitor
of Na+/Mg2+ owing to Mg2+ extrusion and also inhibits Mg2+ inﬂux
via TRPM-like channel [34], attenuated the MPP+-induced [Mg2+]i in-
ﬂux (Fig. 1B). These inhibitors attenuated but not completely sup-
pressed the Mg2+ inﬂux at used concentrations. In imipramine
treated cells, [Mg2+]i and viability were signiﬁcantly higher than
those in the cells in a nominally Mg2+-free culture medium after 16 h
exposure to MPP+ (Fig. 3) analyzed in a Tukey's test. It results from
the incomplete inhibition of Mg2+ inﬂux possibly via TRPM7 by
40 μM of imipramine or 50 μM of 2-APB or an existence of the other
channels or transporters involved in thisMg2+ inﬂux.MPP+ chronically
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16 h (Fig. 2).
MPP+ also induced Mg2+ release from mitochondria. In our previ-
ous study, we showed that MPP+, which acts as an inhibitor of complex
I in mitochondrial electron transfer chain, induces depolarization of mi-
tochondrial membrane potential and decreases in Mg2+ concentration
in mitochondria [25]. Rotenone, which also inhibits complex I, also in-
duced a slight increase in [Mg2+]i that probably resulted from an
Mg2+ release from mitochondria (Fig. S7). These data suggest that
MPP+-induced Mg2+ release from mitochondria occurs concomitantly
with the depolarization of their membrane potential induced by the in-
hibition of electron transfer chain. Although we had demonstrated that
collapse of mitochondrial membrane potential results in Mg2+ release
to cytoplasm [14], what protein permeates Mg2+ is still obscure. One
possible pathway is Mg-ATP/Pi carrier, which exchanges Mg-ATP for Pi
electroneutrally [43]. Since ATP-Mg/Pi carriers are activated by an in-
crease in [Ca2+]i [44], increased [Ca2+]i induced by MPP+ application
might activate this protein resulting in Mg-ATP release from a mito-
chondrial matrix. Recently, Mg2+ exporter protein on mitochondrial
membrane was reported in yeast mitochondria [45]. In mammalian
cells, a similar protein might extrude Mg2+ from a mitochondrial ma-
trix. Because mitochondrial damage is an important hallmark of
human PD, anMg2+ release frommitochondria possibly occurs in dopa-
minergic neurons in PD patients.
MPP+ induced about 150 μM increase in [Mg2+]i via two path-
ways described above. Mg2+ release from mitochondria induced by
rotenone was suppressed by the use of mag-fura-2-AM at 10 μM
(Fig. S7B). It indicates that an increase in [Mg2+]i evoked by the inhi-
bition of complex I (approximately 30 μM) could be chelated bymag-
fura-2 when mag-fura-2-AM was used at 10 μM. Our data shown in
Fig. 4 and S4 indicate that a high concentration of mag-fura-2 also
suppressed the MPP+-induced Mg2+ inﬂux. It seems too high a con-
centration (more than 100 μM) to be chelated by mag-fura-2, even if
the intracellular concentration of mag-fura-2 is higher than the used
concentration of mag-fura-2-AM (10 μM). The Mg2+ inﬂux induced
by MPP+ might require both MPP+ and Mg2+ release from mito-
chondria. There might be a mechanism to amplify the Mg2+ signal.
Intracellular free ion concentration was regulated by inﬂux, efﬂux,
buffering by biological molecules and compartmentalization. Whereas
[Mg2+]i increased immediately after MPP+ application, cellular total
Mg2+ contents increased gradually for 16 h (Figs. 1 and 2). The differ-
ence in the time-course between ionized and total Mg2+ concentration
may reﬂect a change in intracellular Mg2+ buffering molecules and
mechanisms.
4.3. Protective effect of Mg2+ on mitochondrial functions
A decrease in cellular ATP concentration was observed in the cells
exposed to MPP+ in a nominally Mg2+-free culture medium (Fig. 6).
Mitochondrial ATP production is modulated by Mg2+ concentration in
mitochondria [17,18]. The data presented in this study and our previous
study show that MPP+ inducesMg2+ release frommitochondria (Fig. 1
and [25]). This leads to a decrease in mitochondrial ATP production in
MPP+-treated cells. On the other hand, in themedium containing phys-
iological range of Mg2+, Mg2+ inﬂux resulted in a sustained increase in
[Mg2+]i (Figs. 1 and 2). Since mitochondria are one of intracellular
Mg2+ buffers, a part of increased [Mg2+]i likely enters into mitochon-
dria. It maintains Mg2+ concentration in mitochondria higher than
that in the cells without Mg2+ inﬂux treated with MPP+ in a nominally
Mg2+-free culture medium. It would lead to the maintaining of cyto-
plasmic ATP concentration in the cells exposed to MPP+ in other than
nominally Mg2+-free condition.
Cellular ROS production was suppressed by the increased [Mg2+]i,
resulting in the attenuation of MPP+ toxicity (Figs. 3 and 7). ROS is
one of themainmediators of neurodegeneration in PD, and suppression
of ROS generation attenuates neuronal cell death [8,46,47]. However,the contribution of Mg2+ to the regulation of cellular ROS generation
is controversial. Although some studies have indicated that Mg2+ in-
hibits ROS production [19], others have reported that Mg2+ inﬂux
from TRPM7 accelerates ROS generation [48,49]. It was reported that
the expression levels of glutathione S-transferase (GST) increased in
the cells cultured in a low Mg2+ medium, and resulted in the suppres-
sion of cellular ROS levels [50]. Therefore, Mg2+ inﬂux via TRPM7 may
result in the increase in the amount of cellular ROS by suppressing
ROS degradation [48]. On the other hand, Mg2+ inhibits mitochondrial
ROS generation [19]. Impairing the activity of complex I, which is a com-
ponent of mitochondrial electron transfer chain and target of MPP+,
leads to an increase in ROS generation in mitochondria and a subse-
quent decrease in glutathione (GSH) levels [8]. An increase in [Mg2+]i
induced by MPP+ contributed to the inhibition of mitochondrial ROS
generation rather than suppression of ROS degradation. This resulted
in the suppression of cellular ROS generation as shown in Fig. 7.
4.4. Cellular Mg2+ transport and PD
Based on our results, Mg2+ concentration in dopaminergic neurons
is crucial, and higher concentration in cellular basalMg2+ concentration
attenuates but not completely abolished the progress of neurodegener-
ation. Therefore, dysfunction of Mg2+ uptake into dopaminergic neu-
rons, for example decreasing in Mg2+ concentration in brain tissue or
down-regulation of cellular Mg2+ transport proteins, may accelerate
the neurodegeneration in human brains. In this study, we showed that
MPP+ induces Mg2+ inﬂux, although it is still obscure how MPP+ acti-
vatesMg2+ transport protein on cellmembrane.WhereasMPP+ aswell
as rotenone inhibits complex I of mitochondrial electron transfer chain
and elicited Mg2+ release from mitochondria, only MPP+ induced
Mg2+ inﬂux (Fig. 1 and S7). It suggests that Mg2+ inﬂux might not be
elicited depending on causes of PD, because it was not observed in rote-
none model of PD (Fig. S7). This may be a cause of the conﬂict in previ-
ous reports: there are no signiﬁcant difference in Mg2+ concentration
between tissues in PD patients and those in control [51,52], whereas
other studies showed that Mg2+ concentration in tissues in PD patients
were lowered [23,53]. Since mitochondrial damage is a critical event in
human PD, Mg2+ release from mitochondria probably occurs in
patient's brains. Cytoplasmic excess Mg2+ is extruded via Na+/Mg2+
exchangers [54], hence it results in the decrease in cellular Mg2+ con-
centration. It may lead to the lowered Mg2+ concentration in the
brain tissue reported [23,53]. Based on our data, it accelerates neurode-
generation. Whereas symptoms of PD develop in the neurons contain-
ing any concentration of Mg2+, it is ready to occur and progress in the
neurons containing low concentration of Mg2+.
In this study, we observed that imipramine inhibitedMPP+-induced
Mg2+ inﬂux,whereas it is usually used to inhibit Na+/Mg2+ exchangers
for Mg2+ extrusion. It probably inhibited Mg2+ efﬂux via the ex-
changers as well as MPP+-induced Mg2+ inﬂux. Although the inhibi-
tion of Mg2+ efﬂux seems to result in an increase in [Mg2+]i by
accumulating mobilized Mg2+, our data indicate that imipramine in-
hibits MPP+-induced increase in [Mg2+]i. It suggests that [Mg2+]i is
dominantly determined by Mg2+ inﬂux upon the neurodegeneration
in PD.
[Mg2+]i is strictly regulated by many types of Mg2+ speciﬁc chan-
nels and transporters on the cell membrane and on organelles [16,55].
Among those channels and transporters, mutation in TRPM7 has been
reported in some familial PD patients [56,57]. It indicates that dysfunc-
tion of cellular Mg2+ transport is one of the risk factors of PD, since this
channel plays an important role in cellular Mg2+ homeostasis [58,59].
This is consistent with the report that Mg2+ deﬁciency induces degen-
eration of dopaminergic neurons in substantia nigra in rat [42]. In our
experiments, Mg2+ inﬂux, which might be carried by TRPM7 (Fig. 1B),
has a protective effect (Fig. 3). It suggests that this channel plays impor-
tant roles not only in cellular Mg2+ transport but also in neuroprotec-
tion in PD patients. Because it has been shown that down-regulation
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such as SLC41A2 [37], the mutation in TRPM7 does not always lead to
PD [60]. In our experiment, overexpression of SLC41A2 resulted in an at-
tenuation of MPP+ toxicity (Fig. 5B). It suggests that an increase in
[Mg2+]i, wherever mobilized, attenuates the neurodegeneration in PD.
Moreover, expression levels of mRNA encoding SLC41A2 increased in
the progress of PD (Fig. 5C). It might be a cell protection mechanism
against neurodegeneration by increasing [Mg2+]i.
It is likely that Mg2+ channels and transporters also work
compensatorily with each other to maintain [Mg2+]i in vivo. Therefore,
variations of expression levels of those proteins and robustness ofMg2+
transport in neurons might decide a risk of neurodegenerative disorder
in human brain. The progression of PD might also perturb the expres-
sion levels of those proteins, contrarily. Based on these ideas, it seems
to be important to investigate changes in the expression levels of
Mg2+ transport proteins during neurodegeneration and clarify which
protein is sensitive to the progress of neurodegeneration in PD.
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